⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31668225 | 0.97 | — | — | |
| SCHEMBL27220435 | 0.84 | — | — | |
| SCHEMBL17982513 | 0.82 | — | — | |
| SCHEMBL31183974 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL31270270 | 0.77 | — | — | |
| SCHEMBL18151564 | 0.76 | HRH3 (0.31) | — | |
| SCHEMBL2898699 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL21357318 | 0.74 | HRH3 (0.30) | — | |
| SCHEMBL18492722 | 0.74 | — | — | |
| SCHEMBL25335174 | 0.74 | SLC6A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304563-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2025-10-02 | — | — | US | disclosed |
| EP-4490152-A1 | ACTIVATORS OF EFFECTOR T CELLS | Orum Therapeutics Inc. (KR) | 2025-01-15 | — | — | EP | disclosed |
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| WO-2024119277-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-06-13 | — | — | WO | disclosed |
| CN-118165011-A | KRAS inhibitors and uses thereof | 润佳(上海)医药工程有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023170608-A1 | ACTIVATORS OF EFFECTOR T CELLS | ORUM THERAPEUTICS, INC. (KR) | 2023-09-14 | — | — | WO | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-10385055-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-08-20 | — | — | US | disclosed |